Patents by Inventor John Blankenship

John Blankenship has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190367628
    Abstract: The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.
    Type: Application
    Filed: May 30, 2019
    Publication date: December 5, 2019
    Inventors: Aida ABUJOUB, John BLANKENSHIP, Tony FLEMING, Brian HOLMBERG, Connie HONG, Lu HUANG, Haihui LU
  • Publication number: 20190299367
    Abstract: The system includes a forward clamping assembly, steady rests and compression assembly upon which the fuselage of a rocket is secured. The forward clamping assembly secures the forward fuselage of the rocket and the steady rests secure the middle fuselage of the rocket. The compression assembly includes a fluted nozzle rotator which engages the flutes of the nozzle of the rocket. Rotation of the nozzle rotator results in torque being applied to the joint connecting the rocket nozzle with the motor casing of the rocket so as to allow insertion or removal of an Ortman key that secures the motor casing and nozzle.
    Type: Application
    Filed: March 27, 2018
    Publication date: October 3, 2019
    Applicant: United States of America as represented by the Secretary of the Army
    Inventors: John Michael Bush, Christina Blankenship
  • Publication number: 20190261156
    Abstract: Methods and systems for cellular device detection are presented. A signal processing receiver operable to determine a plurality of uplink parameters according to a downlink broadcast message. The signal processing receiver is also configurable to receive an uplink message according to the plurality of uplink parameters, thereby determining a presence and/or an identity of a cellular device by decoding the uplink message.
    Type: Application
    Filed: May 6, 2019
    Publication date: August 22, 2019
    Inventors: Keith Blankenship, John Orlando, Aaron Madsen, Michael Johnson
  • Patent number: 10321295
    Abstract: Methods and systems for cellular device detection are presented. A signal processing receiver operable to determine a plurality of uplink parameters according to a downlink broadcast message. The signal processing receiver is also configurable to receive an uplink message according to the plurality of uplink parameters, thereby determining a presence and/or an identity of a cellular device by decoding the uplink message.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: June 11, 2019
    Assignee: Epiq Solutions
    Inventors: Keith Blankenship, John Orlando, Aaron Madsen, Michael Johnson
  • Publication number: 20180022819
    Abstract: The present disclosure relates to combination treatments with anti-androgen therapeutics, including enzalutamide, and prostate-specific membrane antigen (PSMA)-binding polypeptides including multi-specific polypeptide therapeutics that specifically target cells expressing PSMA and are capable of redirecting T-cell cytotoxicity. Such therapeutics are useful for the treatment of prostate cancer (e.g., castration-resistant prostate cancer). In one embodiment, multi-specific polypeptide therapeutics bind both PSMA-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides compositions comprising the multi-specific polypeptide therapeutics and one or more anti-androgen therapeutics.
    Type: Application
    Filed: February 11, 2016
    Publication date: January 25, 2018
    Inventors: John BLANKENSHIP, Elaine Todd SEWELL
  • Publication number: 20170089885
    Abstract: This disclosure provides a cell-based assay for testing the potency of multispecific binding molecules which specifically bind a T-cell antigen and a target antigen for redirected T-cell-mediated cellular cytotoxicity. The assay uses the TALL-104 T-cell line as effector cells, and provides a sensitive, specific, and reproducible method for ensuring that purity, activity, and stability of multispecific binding molecule batches can be measured for development, clinical trials, and commercial marketing.
    Type: Application
    Filed: March 18, 2015
    Publication date: March 30, 2017
    Inventors: John Blankenship, Elaine Sewell, Richard Lowe
  • Patent number: 7605561
    Abstract: A method for controlling charging of a power source of a hybrid vehicle. The method includes determining a maximum output level of a primary power source, determining a state of charge of a secondary power source, determining a charge torque modifier value based on the maximum output torque level and the state of charge, determining a target torque level for an electrical machine based on the charge torque modifier value, and driving the electrical machine at the target torque level with the primary power source to charge the secondary power source.
    Type: Grant
    Filed: September 22, 2004
    Date of Patent: October 20, 2009
    Assignee: Ford Global Technologies, LLC
    Inventors: Mark Yamazaki, John Blankenship, Francis T. Connolly
  • Publication number: 20070256737
    Abstract: A gaseous fuel management system for an automotive vehicle includes at least one gas sensor for detecting the presence of gaseous fuel outside of the confines of the vehicle's fuel storage tank, fuel lines, and prime mover. In the event that fugitive gas is detected and the concentration exceeds a predetermined threshold, the fuel supply to the vehicle's prime mover will be shut off and, if so equipped, the vehicle may then be operated in a battery power mode for the convenience of the driver.
    Type: Application
    Filed: June 24, 2004
    Publication date: November 8, 2007
    Inventors: Suriyaprakash Janarthanam, John Blankenship, Steven Szwabowski, Anthony Grabowski, Arun Jaura, Theodore Filippi, Michael Brown, Richard Soltis, John Grabowski
  • Publication number: 20060061322
    Abstract: A method for controlling charging of a power source of a hybrid vehicle. The method includes determining a maximum output level of a primary power source, determining a state of charge of a secondary power source, determining a charge torque modifier value based on the maximum output torque level and the state of charge, determining a target torque level for an electrical machine based on the charge torque modifier value, and driving the electrical machine at the target torque level with the primary power source to charge the secondary power source.
    Type: Application
    Filed: September 22, 2004
    Publication date: March 23, 2006
    Applicant: FORD GLOBAL TECHNOLOGIES, LLC
    Inventors: Mark Yamazaki, John Blankenship, Francis Connolly
  • Patent number: 5730713
    Abstract: This invention provides a composition, device and method for the removal of selected factors, such as cytokines or pharmaceuticals, from a substance such as whole blood or plasma. Advantageously, the invention provides for the treatment or prevention of septic shock syndrome or other conditions evidenced by the presence of cytokines in a patient by contacting the patient's whole blood with a composition comprising silica and a surface treatment material, such as heparin, but preferably human serum albumin (HSA). The treatment lowers the cytokine concentration of the blood. Pharmaceuticals can be removed from an individual's whole blood or plasma, such as for use in treating drug overdosage.
    Type: Grant
    Filed: June 3, 1996
    Date of Patent: March 24, 1998
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: Thomas B. Okarma, John Blankenship, Abraham T. Lin, Mohammad A. Elkalay
  • Patent number: 5523096
    Abstract: This invention provides a composition, device and method for the removal of selected factors, such as cytokines or pharmaceuticals, from a substance such as whole blood or plasma. Advantageously, the invention provides for the treatment or prevention of septic shock syndrome or other conditions evidenced by the presence of cytokines in a patient by contacting the patient's whole blood with a composition comprising silica and a surface treatment material, such as heparin, but preferably human serum albumin (HSA). The treatment lowers the cytokine concentration of the blood. Pharmaceuticals can be removed from an individual's whole blood or plasma, such as for use in treating drug overdosage.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: June 4, 1996
    Assignee: Applied Immune Sciences, Inc.
    Inventors: Thomas B. Okarma, John Blankenship, Abraham T. Lin, Mohammad A. Elkalay
  • Patent number: 5437861
    Abstract: This invention provides a composition, device and method for the treatment or prevention of septic shock syndrome or other conditions evidenced by the presence of cytokines in a patient by contacting the patient's whole blood with a composition comprising silica and a surface treatment material, such as heparin, but preferably human serum albumin (HSA). The treatment lowers the cytokine concentration of the blood.
    Type: Grant
    Filed: March 16, 1993
    Date of Patent: August 1, 1995
    Assignee: Applied Immune Sciences, Inc.
    Inventors: Thomas B. Okarma, John Blankenship, Abraham T. Lin, Mohammad A. Elkalay
  • Patent number: D536758
    Type: Grant
    Filed: March 16, 2006
    Date of Patent: February 13, 2007
    Inventor: John Blankenship
  • Patent number: D564053
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: March 11, 2008
    Inventor: John Blankenship